Vanda Pharmaceuticals
VNDA
173 hedge funds and large institutions have $611M invested in Vanda Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 67 increasing their positions, 60 reducing their positions, and 25 closing their positions.
243% more call options, than puts
Call options by funds: $901K | Put options by funds: $263K
12% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 60
4% less capital invested
Capital invested by funds: $637M → $611M (-$26.1M)
1.69% less ownership
Funds ownership: 100.68% → 98.99% (-1.7%)
8% less funds holding
Funds holding: 188 → 173 (-15)
44% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$12.4M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$9.85M |
| 3 |
Renaissance Technologies
New York
|
+$4.43M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.32M |
| 5 |
Millennium Management
New York
|
+$3.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSV Asset Management
Chicago,
Illinois
|
-$22.1M |
| 2 |
Bank of New York Mellon
New York
|
-$6.87M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$3.61M |
| 4 |
State Street
Boston,
Massachusetts
|
-$3.6M |
| 5 |
JP Morgan Chase
New York
|
-$2.68M |
VNDA Hedge Fund Activity: Q2 2022 in Review
173 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q2 2022, worth a combined $611M — down 4.1% from $637M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of VNDA and 14 opened new positions — a net loss of 11 holders — while 60 trimmed existing stakes and 67 added.
The largest buyer was Assenagon Asset Management, adding an estimated $12.4M. The largest seller was LSV Asset Management, cutting an estimated $22.1M.
- 173 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q2 2022, down from 188 in Q1 2022.
- Funds reported $611M of Vanda Pharmaceuticals stock for Q2 2022, down 4.1% quarter-over-quarter.
- 14 funds opened new Vanda Pharmaceuticals positions in Q2 2022 and 25 closed out, a net change of -11 holders.
- The largest Vanda Pharmaceuticals buyer in Q2 2022 was Assenagon Asset Management, an estimated $12.4M added.
- The largest Vanda Pharmaceuticals seller in Q2 2022 was LSV Asset Management, an estimated $22.1M sold.
Based on aggregated 13F filings for Q2 2022.